Sandoz inks deal with Adalvo to sell 6 generics in the U.S.
Sandoz has signed a distribution and collaboration agreement with Adalvo for exclusive Sandoz rights to commercialize six products in the United States across key therapeutic areas, including antifungal/antibiotic, oncology and pulmonary.
“Sandoz is putting patients first by securing the rights to bring more affordable, equally effective treatments for a range of disorders that collectively affect millions of people in the U.S. every year,” said Keren Haruvi, president of Sandoz. “This agreement also helps advance our ambition to be the world’s largest and most valued generics company.”
Read more: Novartis launches strategic review of its Sandoz generic drugs unit]
These products, which are slated for near- to mid-term launches beginning in 2024, have a total addressable market size of approximately $3 billion, further advancing the Sandoz product pipeline in the key U.S. generics market.
[Read more: Novartis to separate Sandoz generics drug unit into standalone company]
“The agreement also demonstrates the unwavering Sandoz commitment to pioneering patient access to critical medicines in areas of greatest unmet need. In addition to building out the Sandoz U.S. offering in these key areas, the antibiotic products also would underpin the Sandoz strategy of combatting the global spread of antimicrobial resistance by driving responsible access to a broad range of appropriate treatments,” the company said.